Obesity Clinical Trial
— CHARGEOfficial title:
Targeting Food Cue Reactivity and Satiety Sensitivity to Decrease Binge Eating and Weight
Verified date | May 2023 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of this proposed study are: 1) to evaluate feasibility and acceptability of a novel intervention, Regulation of Cues (ROC), and Cognitive Behavior Therapy (CBT), and 2) to evaluate the efficacy of both treatments on reduction of binge eating and weight loss among 120 Veterans with subclinical or clinical Binge Eating Disorder (BED) with comorbid overweight/obesity (OW/OB).
Status | Completed |
Enrollment | 129 |
Est. completion date | April 30, 2023 |
Est. primary completion date | March 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. All participants will be Veterans between the ages of 18-65 meeting criteria for overweight, with a 45= BMI =25. 2. Participants will meet Diagnostic and Statistical Manual-5 (DSM-5) criteria for BED or subclinical BED 3. Participants will be willing and able to participate in assessment visits and treatment sessions at University of California, San Diego (UCSD). 4. Participants will be able to provide data in English through interviews and questionnaires and understand treatment materials in English. 5. Participants will be willing to maintain contact with the investigators for 11 months. 6. Participants will be free of serious or unstable medical (current symptoms of angina, stroke, heart disease or other serious medical condition that would make physical activity unsafe or impossible at a moderate level) or psychiatric illness (i.e., active suicidal ideation, history of suicide attempt within 1 year, current unmanaged psychosis, manic episode, anorexia nervosa, bulimia nervosa, or substance abuse within the past year) or psychosocial instability (e.g., homelessness) that could compromise study participation. 7. Participants will be free from conditions in which exercise or weight loss will be detrimental to the participant's health (e.g., pregnancy); pharmacotherapy for obesity or binge eating disorder (e.g., Orlistat or Meridia) or bariatric surgery within the past 6 months or planning to start such treatments in the next 11 months. 8. Participants will not be moving out of the San Diego area for the duration of their study enrollment (11 months). 9. Participants will not be pregnant, planning to get pregnant in the 11-month study period or lactating. 10. Participants will not be participating in group or individual psychotherapy for binge eating or weight management. 11. Participants with medical or psychological problems or taking medications that could make adherence with the study protocol difficult or dangerous will not be included. |
Country | Name | City | State |
---|---|---|---|
United States | UCSD Center for Healthy Eating and Activity Research (CHEAR) | La Jolla | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego | San Diego Veterans Healthcare System, United States Department of Defense |
United States,
Boutelle KN, Zucker N, Peterson CB, Rydell S, Carlson J, Harnack LJ. An intervention based on Schachter's externality theory for overweight children: the regulation of cues pilot. J Pediatr Psychol. 2014 May;39(4):405-17. doi: 10.1093/jpepsy/jst142. Epub 2014 Jan 23. — View Citation
Boutelle KN, Zucker NL, Peterson CB, Rydell SA, Cafri G, Harnack L. Two novel treatments to reduce overeating in overweight children: a randomized controlled trial. J Consult Clin Psychol. 2011 Dec;79(6):759-71. doi: 10.1037/a0025713. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Attendance | The number of treatment visits attended | Post-Treatment (5 months following baseline) | |
Primary | Acceptability | Average likert ratings to questions, such as "How much did you enjoy the treatment?" and "How helpful did you find the treatment?" | Post-Treatment (5 months following baseline) | |
Primary | Binge Eating as measured by the Eating Disorder Examination (EDE) | Diagnosis of Binge Eating Disorder (BED) and subclinical BED, number of OBEs (large amount of food and loss of control), objective overeating episodes (large amount of food without loss of control), and SBEs (lack of large amount of food with loss of control) determined by responses to the EDE. | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks | |
Primary | Binge Eating as measured by the Binge Eating Scale (BES) | Dimensional score of binge eating consisting of items to describe binge eating behaviors and feelings and cognitions associated with binge eating. | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks | |
Primary | Binge Eating as measured by the Eating Disorder Examination-Questionnaire (EDE-Q) | Three question items from the questionnaire to calculate the number of binge eating episodes and number of days participants experienced a binge eating episode. | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks | |
Primary | Body Mass Index (BMI) as measured by weight and height | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks | ||
Primary | Energy intake | Calorie intake estimated by 24-hour dietary recalls on 3 non-consecutive days | Changes from baseline at an average of 20 weeks and 44 weeks | |
Secondary | Satiety Responsiveness | Self-reported satiety responsiveness measured by the Adult Eating Behavior Questionnaire (AEBQ) | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks | |
Secondary | Food Responsiveness | Self-reported food responsiveness measured by the Adult Eating Behavior Questionnaire (AEBQ) | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks | |
Secondary | Reward-Based Eating | Scales to evaluate reward-related eating measured by the Reward-Based Eating Drive Scale (RED-13) | Changes from baseline at an average of 9 weeks, 20 weeks, and 44 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |